Rules 4.7.3 and 4.10.3 ASX Listing Rules Appendix 4G (current at 17/7/2020) Page 1 Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations Name of entity BCAL Diagnostics Limited ABN/ARBN Financial year ended: 51 142 051 223 30 June 2026 ...
Appendix 4G and Corporate Governance Statement
Filed with ASX ·
6ix hasn’t read this filing yet.
BCAL Diagnostics Limited on 6ix
Earlier from BCAL Diagnostics
- BCAL Takes Interest in Genetic Signatures to 18.46%
- Change in Substantial Shareholder Notice for GSS
- Notification regarding unquoted securities - BDX
- BCAL Secures Funding for FY2027 Update
- Proposed issue of securities - BDX
Later from BCAL Diagnostics
- Appendix 4E and Annual Report to shareholders
- Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
- Investor Presentation September 2026
- BCAL Seeks Board Change at Genetic Signatures
- Clarification of BCAL's Position in Relation to GSS
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics